In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Matthew P ZimmermanDepartment of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-2979-9624 Emily K CoxLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Wan Lin ChongLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Alexander G BastianLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Katherine VietorLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Yacine ChoutriDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0009-0007-8155-197X Jenna CollierDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4071-4986 Vasyl ZhabotynskyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1575-5732 Haiyang WangLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Sarah A WeissDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Jia-Ren LinHarvard Ludwig Center and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA.ORCID 0000-0003-4702-7705 Tuulia ValliusHarvard Ludwig Center and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA.
Shishir M PantHarvard Ludwig Center and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA.ORCID 0000-0002-2686-7898 Peter K SorgerHarvard Ludwig Center and Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA.ORCID 0000-0002-3364-1838 Willy HugoDepartment of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California, USA.ORCID 0000-0002-1426-7190 Debattama R SenDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0947-8284 Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9736-2109 Brian C MillerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-5931-4184 Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MTraining Program in Cellular Systems and Integrative PhysiologyT32GM133364 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kathleen M Caron, Natasha T Snider · 2020 to 2026
$1.4MTargeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer MutationsK08CA248960 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MILLER, BRIAN C · 2020 to 2024
$1.2MNCI NIH HHS K08 CA248960NCI NIH HHS P30 CA016086NCI NIH HHS P50 CA211015NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM133364
6 · The paper itselfAbstract
Background: Resistance to immune checkpoint inhibitors represents a major therapeutic challenge, as less than 50% of patients with melanoma achieve long-term response to immune checkpoint inhibitor therapy. One mechanism of acquired resistance involves somatic mutations, such as loss of beta-2 microglobulin ( Methods: This study used single-cell RNA-seq, flow cytometry, and Results: We found an increase in immunosuppressive macrophages in Conclusions: These data demonstrate that CD8
Indexed as
Immune Checkpoint InhibitorMajor Histocompatibility Complex - MHCMonocytesT-Lymphocytes
Identifiers
PMID41676732
PMCPMC12889677
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390